Compare Stocks → Warning: Don’t type “Trump” on your phone (Feds could be watching) (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AUPHNASDAQ:PRNBNASDAQ:RARXNASDAQ:THORNASDAQ:TPTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$4.99-0.2%$5.67$4.85▼$12.43$721.65M1.362.21 million shs668,421 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/ARARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shsTHORSynthorx$67.99$67.99$11.05▼$71.90$2.20BN/A474,507 shsN/ATPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-0.79%-2.15%-3.29%-36.47%-53.53%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%THORSynthorx0.00%0.00%0.00%0.00%0.00%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%Warning: Don’t type “Trump” on your phone (Feds could be watching) (Ad)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals1.0292 of 5 stars3.41.00.00.02.50.00.6PRNBPrincipia BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals2.75Moderate Buy$10.00100.40% UpsidePRNBPrincipia BiopharmaN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest RARX, THOR, AUPH, TPTX, and PRNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/1/2024AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.002/23/2024AUPHAurinia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $10.002/22/2024AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $13.002/16/2024AUPHAurinia PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold$9.50 ➝ $9.002/16/2024AUPHAurinia PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $8.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$175.51M4.11N/AN/A$2.63 per share1.90PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14RARXRa Pharmaceuticals$3M757.11N/AN/A$5.56 per share8.63THORSynthorxN/AN/AN/AN/A$6.72 per shareN/ATPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M-$0.54N/A9.07N/A-44.45%-20.10%-14.84%5/2/2024 (Confirmed)PRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/ARARXRa Pharmaceuticals-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/ATHORSynthorx-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/ATPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest RARX, THOR, AUPH, TPTX, and PRNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AAUPHAurinia Pharmaceuticals-$0.17N/A+$0.17N/AN/AN/A 2/15/202412/31/2023AUPHAurinia Pharmaceuticals-$0.16-$0.19-$0.03-$0.19$45.00 million$45.10 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/ATHORSynthorxN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.205.504.99PRNBPrincipia BiopharmaN/A17.0117.01RARXRa Pharmaceuticals0.0114.7814.79THORSynthorxN/A18.8718.87TPTXTurning Point TherapeuticsN/A16.8316.83OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%PRNBPrincipia Biopharma95.54%RARXRa PharmaceuticalsN/ATHORSynthorx66.12%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals4.30%PRNBPrincipia Biopharma16.01%RARXRa Pharmaceuticals4.30%THORSynthorx53.20%TPTXTurning Point Therapeutics8.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300144.62 million138.40 millionOptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableRARXRa Pharmaceuticals7247.33 millionN/AOptionableTHORSynthorx4832.34 millionN/ANot OptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableRARX, THOR, AUPH, TPTX, and PRNB HeadlinesSourceHeadlineGlass System in Turning Point Residencearchdaily.com - April 2 at 10:51 AMBid to remove prosecutors sets up turning point in Trump’s Georgia casepolitico.com - February 19 at 11:51 PMTurning Point Brands Inc.wsj.com - February 17 at 11:42 PMAlzheimer’s: A Turning Point?bbc.co.uk - February 12 at 4:29 PMTurning Point Brands Inc (TPB)investing.com - February 10 at 7:36 PMCormorant Asset Management, LP's Net Worthbenzinga.com - February 10 at 7:36 PMSolving quadratic equations - Edexcelbbc.co.uk - January 15 at 9:15 AMCOP15: A Turning Point for Investor Approaches to Biodiversitymorningstar.com - December 19 at 12:52 PMTurning Point USA: Are conservatives fighting back on campus?bbc.com - December 16 at 3:14 PMBMS bet looking good as Augtyro approved in ROS1-positive NSCLCthepharmaletter.com - November 16 at 12:30 PMPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodulster.ac.uk - October 29 at 7:58 PMA Turning Point for Japan-US Climate Cooperation?thediplomat.com - October 28 at 1:00 PMWhat to know about the Turning Point USA incident on Arizona State University's campusazcentral.com - October 28 at 1:00 PMRight-wingers start to turn on this pro-Trump propaganda groupmsnbc.com - October 28 at 1:00 PMUAW, Detroit Three careen toward another Friday turning pointautoblog.com - October 16 at 6:04 PMTrump's youth whisperers living large as MAGA candidates failmsnbc.com - October 14 at 1:16 PMSong Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...Song Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...koimoi.com - October 5 at 8:10 AMThe revised economic figures are a huge lucky break for Sunak – and could be a turning pointindependent.co.uk - September 17 at 4:14 PMDespite previous campus firestorm, Turning Point USA to welcome conservative speakers at ASUazcentral.com - September 15 at 12:34 AMThis law may be the turning point in America’s fight to save the planetmsnbc.com - August 21 at 7:44 AMTattoos have reached a turning point at workft.com - July 29 at 11:36 PMTurning Point’s #ACTCON was a pro-Trump lovefest designed to intimidatemsnbc.com - July 25 at 10:25 AM‘Turning point’ in the fight against Alzheimer’s as drug found to slow diseaseindependent.co.uk - July 23 at 3:37 PMMargaret Thatcher, a turning point in British politicsen.mercopress.com - July 19 at 12:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAurinia PharmaceuticalsNASDAQ:AUPHAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Principia BiopharmaNASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Ra PharmaceuticalsNASDAQ:RARXRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.SynthorxNASDAQ:THORSynthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.Turning Point TherapeuticsNASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.